• Amprius Technologies’ third-quarter 2026 net loss attributable to common stockholders narrowed 10% year over year to $3.5 million.
• Revenue climbed 83% year over year to $39.1 million, while gross margin reached 27%.
• It secured a $75 million U.S. Department of War contract supporting domestic cell production, with planned output starting in 2028.
• The 2026 revenue outlook rose to $145 million, with net loss expected below $10 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amprius Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611101605BIZWIRE_USPR_____20261110_BW308758) on November 10, 2026, and is solely responsible for the information contained therein.